Spots Global Cancer Trial Database for intravesical

Every month we try and update this database with for intravesical cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer	NCT01687244	Superficial Bla...	INSTILADRIN	18 Years -	FKD Therapies Oy
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder	NCT01259063	Bladder Cancer	Everolimus and ...	18 Years -	Memorial Sloan Kettering Cancer Center
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer	NCT01373294	Bladder Cancer	Bacille Calmett... Lenalidomide	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder	NCT02202772	Urothelial Carc...	Cabazitaxel Gemcitabine Cisplatin	18 Years -	Columbia University
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer	NCT00384891	Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si...	Synergo + MMC Bacillus Calmet...	18 Years -	Medical Enterprises Europe B.V.
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer	NCT03022825	Bladder Cancer	N-803 and BCG N-803	18 Years -	ImmunityBio, Inc.
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer	NCT02311101	Urinary Bladder...	Mitomycin C	18 Years -	The University of Texas Health Science Center at San Antonio
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer	NCT02311101	Urinary Bladder...	Mitomycin C	18 Years -	The University of Texas Health Science Center at San Antonio
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer	NCT02311101	Urinary Bladder...	Mitomycin C	18 Years -	The University of Texas Health Science Center at San Antonio
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer	NCT01687244	Superficial Bla...	INSTILADRIN	18 Years -	FKD Therapies Oy
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer	NCT01162785	Bladder Cancer	SCH 721015	18 Years -	M.D. Anderson Cancer Center
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy	NCT03171493	Urothelial Carc...	MV-NIS	18 Years -	Vyriad, Inc.
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC	NCT04819399	Urinary Bladder...	Catumaxomab	18 Years -	Lindis Biotech GmbH
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer	NCT00696579	Bladder Cancer	BCG gemcitabine	18 Years - 75 Years	University Of Perugia
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder	NCT01259063	Bladder Cancer	Everolimus and ...	18 Years -	Memorial Sloan Kettering Cancer Center
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC	NCT04819399	Urinary Bladder...	Catumaxomab	18 Years -	Lindis Biotech GmbH

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: